| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Epidemiology and Biostatistics Program, Division of Cancer Etiology, National Cancer Institute, Bethesda, Maryland 20892 [J. E. G., A. M. G., A. F. K., M. G. D., J. F. F., F. P. L.], and Dana Farber Cancer Institute, Boston, Massachusetts 02115 [J. E. G., M. G. D., F. P. L.]
The Li-Fraumeni cancer family syndrome is manifested by susceptibility to breast cancer, sarcomas, and other neoplasms in children and young adults. The present study utilized clinical follow-up data on 545 members of 24 Li-Fraumeni kindreds living and cancer-free at family ascertainment. Two hypotheses were tested based on a model of autosomal dominant genetic predisposition: (a) that syndrome cancers would continue to occur excessively during follow-up compared to the general population, and (b) that the tumors would occur primarily among those family members likely to carry the gene. Population cancer rates were compared with cancer rates in follow-up of the cohort from ascertainment to 1988. Risk of carrying the gene for the syndrome at the time of ascertainment was calculated for each family member under two models with somewhat different definitions of affection with the syndrome. Cancer occurrence after ascertainment was then analyzed according to the risks. Cancer did continue to occur excessively among the entire cohort during follow-up [relative risk (RR 2.1)]. The excess was greatest below age 20 (RR 21.1), declined with increasing age, and was most pronounced for neoplasms featured in the syndrome (RR 18.2). Among persons less than age 45, at least 87% of cancers occurred in those at higher risk of carrying the gene under both genetic models (RR 22.9 and 21.3). The clinical data, therefore, reliably identify individuals likely to carry a dominantly inherited gene conferring susceptibility to a specific constellation of neoplasms. Recent identification of a germ line mutation in the tumor suppressor gene p53 in persons with the syndrome may, if confirmed, have implications for ultimately defining the component tumors of the syndrome and for the causes and prevention of those tumors arising outside these families.
1 To whom requests for reprints should be addressed, at Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02215.
Received 5/23/91. Accepted 9/11/91.
This article has been cited by other articles:
|
|
 |
|
  K D Gonzalez, C H Buzin, K A Noltner, D Gu, W Li, D Malkin, and S S Sommer High frequency of de novo mutations in Li-Fraumeni syndrome J. Med. Genet., October 1, 2009; 46(10): 689 - 693. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. D. Gonzalez, K. A. Noltner, C. H. Buzin, D. Gu, C. Y. Wen-Fong, V. Q. Nguyen, J. H. Han, K. Lowstuter, J. Longmate, S. S. Sommer, et al. Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations J. Clin. Oncol., March 10, 2009; 27(8): 1250 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Lan, L. Zhang, M. Shen, W. J. Jo, R. Vermeulen, G. Li, C. Vulpe, S. Lim, X. Ren, S. M. Rappaport, et al. Large-scale evaluation of candidate genes identifies associations between DNA repair and genomic maintenance and development of benzene hematotoxicity Carcinogenesis, January 1, 2009; 30(1): 50 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Chen, J. Liang, Z. Wang, X. Zhou, L. Chen, M. Li, D. Xie, Z. Hu, H. Shen, and H. Wang Association of Common PALB2 Polymorphisms with Breast Cancer Risk: A Case-Control Study Clin. Cancer Res., September 15, 2008; 14(18): 5931 - 5937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Masciari, A. D. Van den Abbeele, L. R. Diller, I. Rastarhuyeva, J. Yap, K. Schneider, L. Digianni, F. P. Li, J. F. Fraumeni Jr, S. Syngal, et al. F18-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography Screening in Li-Fraumeni Syndrome JAMA, March 19, 2008; 299(11): 1315 - 1319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Begg, R. W. Haile, A. Borg, K. E. Malone, P. Concannon, D. C. Thomas, B. Langholz, L. Bernstein, J. H. Olsen, C. F. Lynch, et al. Variation of Breast Cancer Risk Among BRCA1/2 Carriers JAMA, January 9, 2008; 299(2): 194 - 201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. L. Sprague, A. Trentham-Dietz, M. Garcia-Closas, P. A. Newcomb, L. Titus-Ernstoff, J. M. Hampton, S. J. Chanock, J. L. Haines, and K. M. Egan Genetic variation in TP53 and risk of breast cancer in a population-based case control study Carcinogenesis, August 1, 2007; 28(8): 1680 - 1686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wirtenberger, S. Tchatchou, K. Hemminki, J. Schmutzhard, C. Sutter, R. K. Schmutzler, A. Meindl, B. Wappenschmidt, M. Kiechle, N. Arnold, et al. Associations of genetic variants in the estrogen receptor coactivators PPARGC1A, PPARGC1B and EP300 with familial breast cancer Carcinogenesis, November 1, 2006; 27(11): 2201 - 2208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wirtenberger, B. Frank, K. Hemminki, R. Klaes, R. K. Schmutzler, B. Wappenschmidt, A. Meindl, M. Kiechle, N. Arnold, B. H.F. Weber, et al. Interaction of Werner and Bloom syndrome genes with p53 in familial breast cancer Carcinogenesis, August 1, 2006; 27(8): 1655 - 1660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wirtenberger, S. Tchatchou, K. Hemminki, R. Klaes, R. K. Schmutzler, J. L. Bermejo, B. Chen, B. Wappenschmidt, A. Meindl, C. R. Bartram, et al. Association of genetic variants in the Rho guanine nucleotide exchange factor AKAP13 with familial breast cancer Carcinogenesis, March 1, 2006; 27(3): 593 - 598. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Harris, G. Gil, H. Robins, W. Hu, K. Hirshfield, E. Bond, G. Bond, and A. J. Levine Detection of functional single-nucleotide polymorphisms that affect apoptosis PNAS, November 8, 2005; 102(45): 16297 - 16302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Kenney, Y. Yasui, P. D. Inskip, S. Hammond, J. P. Neglia, A. C. Mertens, A. T. Meadows, D. Friedman, L. L. Robison, and L. Diller Breast Cancer after Childhood Cancer: A Report from the Childhood Cancer Survivor Study Ann Intern Med, October 19, 2004; 141(8): 590 - 597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H Hampel, K Sweet, J A Westman, K Offit, and C Eng Referral for cancer genetics consultation: a review and compilation of risk assessment criteria J. Med. Genet., February 1, 2004; 41(2): 81 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Thull and V. G. Vogel Recognition and Management of Hereditary Breast Cancer Syndromes Oncologist, February 1, 2004; 9(1): 13 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Wooster and B. L. Weber Breast and Ovarian Cancer N. Engl. J. Med., June 5, 2003; 348(23): 2339 - 2347. [Full Text] [PDF]
|
|
|
|
|
|
M M de Jong, I M Nolte, G J te Meerman, W T A van der Graaf, J C Oosterwijk, J H Kleibeuker, M Schaapveld, and E G E de Vries Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility J. Med. Genet., April 1, 2002; 39(4): 225 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Fox, B. J. Sheppard, C. A. Dangler, M. T. Whary, M. Ihrig, and T. C. Wang Germ-Line p53-targeted Disruption Inhibits Helicobacter-induced Premalignant Lesions and Invasive Gastric Carcinoma through Down-Regulation of Th1 Proinflammatory Responses Cancer Res., February 1, 2002; 62(3): 696 - 702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. B. Lee, S. H. Kim, D. W. Bell, D. C. R. Wahrer, T. A. Schiripo, M. M. Jorczak, D. C. Sgroi, J. E. Garber, F. P. Li, K. E. Nichols, et al. Destabilization of CHK2 by a Missense Mutation Associated with Li-Fraumeni Syndrome Cancer Res., November 1, 2001; 61(22): 8062 - 8067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Nichols, D. Malkin, J. E. Garber, J. F. Fraumeni Jr., and F. P. Li Germ-line p53 Mutations Predispose to a Wide Spectrum of Early-onset Cancers Cancer Epidemiol. Biomarkers Prev., February 1, 2001; 10(2): 83 - 87. [Abstract] [Full Text]
|
|
|
|
|
|
A. CHOMPRET, A. ABEL, D. STOPPA-LYONNET, L. BRUGIÈRES, S. PAGÈS, J. FEUNTEUN, and C. BONAÏTI-PELLIÉ Sensitivity and predictive value of criteria for p53 germline mutation screening J. Med. Genet., January 1, 2001; 38(1): 43 - 47. [Full Text]
|
|
|
|
 |
|
 B. Gerdes, A. Ziegler, A. Ramaswamy, A. Wild, P. Langer, and D. K Bartsch Multiple primaries in pancreatic cancer patients: indicator of a genetic predisposition? Int. J. Epidemiol., December 1, 2000; 29(6): 999 - 1003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. PORTWINE, J. LEES, S. VERSELIS, F. P LI, and D. MALKIN Absence of germline p16INK4a alterations in p53 wild type Li-Fraumeni syndrome families J. Med. Genet., August 1, 2000; 37(8): 13e - 13. [Full Text]
|
|
|
|
|
|
F. P. Li Cancer Control in Susceptible Groups: Opportunities and Challenges J. Clin. Oncol., January 1, 1999; 17(2): 719 - 719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Singh, C. L. Shields, P. De Potter, J. A. Shields, B. Trock, J. Cater, and D. Pastore Familial Uveal Melanoma: Clinical Observations on 56 Patients Arch Ophthalmol, April 1, 1996; 114(4): 392 - 399. [Abstract] [PDF]
|
|
|
|
|
|
J. H. Olsen, J. D. Boice, N. Seersholm, A. Bautz, and J. F. Fraumeni Cancer in the Parents of Children with Cancer N. Engl. J. Med., December 14, 1995; 333(24): 1594 - 1599. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
